Detalles de la búsqueda
1.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 267-276, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539744
2.
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
Gynecol Oncol
; 161(3): 825-831, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33781554
3.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462317
4.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33931498
5.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Gynecol Oncol
; 154(1): 83-88, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31029508
6.
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Gynecol Oncol
; 144(2): 256-259, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27993479
7.
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Lancet Oncol
; 17(8): 1137-1146, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27402147
8.
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Gynecol Oncol
; 142(3): 465-70, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27184721
9.
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).
Gynecol Oncol
; 143(3): 532-538, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717490
10.
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?
Gynecol Oncol
; 136(2): 230-4, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25527364
11.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 15(4): 396-405, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24582486
12.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
J Clin Oncol
; 42(13): 1488-1498, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38315944
13.
Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.
Gynecol Oncol
; 125(3): 673-6, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22446621
14.
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Crit Rev Oncol Hematol
; 66(3): 229-36, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18243011
15.
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
BMC Cancer
; 8: 252, 2008 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18761742
16.
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
J Clin Oncol
; 35(29): 3347-3353, 2017 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28825853
17.
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Oncology
; 71(5-6): 320-6, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17878745
18.
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
BMC Cancer
; 6: 202, 2006 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16882344
19.
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.
Oncotarget
; 7(45): 72654-72661, 2016 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27655643
20.
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
J Clin Oncol
; 29(27): 3628-35, 2011 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21844495